Search clinical trials for: varenicline (CP-526,555)

Total 1060 results

Pfizer

Completed

12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.

Smoking Cessation

United States
Pfizer

Completed

12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation

Smoking Cessation

Japan
Pfizer

Completed

An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation

Smoking Cessation

United States, United Kingdom, Belgium, France, Netherlands
Pfizer

Completed

A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline

Smoking Cessation

United States, Australia
Pfizer

Completed

A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation

Smoking Cessation

United States
Pfizer

Completed

12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation

Smoking Cessation

United States
Pfizer

Completed

A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation

Smoking Cessation

United States, Canada, Norway, Sweden, United Kingdom, Czech Republic, Denmark
Pfizer

Completed

A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

Smoking Cessation

United States
Pfizer

Completed

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets

Smoking Cessation
Pfizer

Completed

A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation

Smoking Cessation

United States
Pfizer

Completed

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

Smoking Cessation

United States, Canada
Pfizer

Completed

Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use

Tobacco Use Cessation

Norway, Sweden
Pfizer

Completed

Varenicline Observational Investigation In The Cessation of Smoking (CHOICES)

Smoking Cessation

Belgium, Hungary, Greece, Slovenia
Pfizer

Completed

A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking

Smoking

Japan
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers

Tobacco Use Disorder

United States
Oyster Point Pharma, Inc.

Completed

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

Healthy Subjects

United States
Pfizer

Completed

Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking

Smoking Cessation

Colombia, Mexico, Egypt, Jordan, Brazil, Costa Rica, Lebanon, Saudi Arabia, South Africa, United Arab Emirates, Venezuela
NYU Langone Health
Pfizer

Withdrawn

Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt (VarenSmoke)

Nicotine Dependence

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Varenicline and Combined NRT for Smoking Cessation

Tobacco Use Disorder | Cigarette Smoker

United States
American University of Beirut Medical Center
Pfizer

Completed

Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation

Nicotine Dependence

Lebanon
Assistance Publique - Hôpitaux de Paris

Unknown

Randomized Trial of Electronic Cigarettes With or Without Nicotine in Smoking Cessation. (ECSMOKE)

Smoking Cessation | Smoking, Cigarette | Electronic Cigarette

France
Pfizer

Completed

A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.

Smoking Cessation

United States
Arizona State University
National Institute on Drug Abuse (NIDA); Pfizer; University of Nevada, Reno; Los...

Completed

Varenicline OTC Trial on Efficacy and Safety (VOTC)

Smoking Cessation | Withdrawal Symptoms | Tobacco Dependence

United States
Pfizer

Withdrawn

A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking Cessation

Smoking Cessation
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)

Completed

An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers

Methamphetamine Addiction | Crystal Meth Addiction | Amphetamine Addiction

United States
Brigham and Women's Hospital

Recruiting

CP101 for the Treatment of Ulcerative Colitis

Ulcerative Colitis

United States
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis

Psoriasis

Japan
Pfizer

Terminated

A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

Obesity

United States, Australia, Canada, Brazil, Slovakia, Czech Republic, Argentina, Germany, Mexico, United Kingdom, Sweden
Korea University Anam Hospital

Completed

A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1502

Healthy

Korea, Republic of
Butler Hospital
Brown University

Completed

Study of Mood Effects of Varenicline (Chantix) in Depressed Outpatient Smokers

Depressive Disorder | Smoking

United States
Medical University of South Carolina

Completed

Hollings Cancer Center Varenicline Sampling Study

Smoking | Smoking Cessation | Smoking, Tobacco | Smoking, Cigarette

United States
Siemens Molecular Imaging

Terminated

Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects

Breast Cancer

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Enrolling by invitation

Cessation Screening Project

Nicotine Dependence

United States
Pfizer

Completed

Smoking Cessation Study In Healthy Adolescent Smokers

Smoking Cessation

United States, Korea, Republic of, Taiwan, Canada, Georgia, Russian Federation
Pfizer

Terminated

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

Obesity

Australia, United States, Korea, Republic of, Spain, France, United Kingdom, Germany, Sweden, Argentina, Chile, Mexico
Pfizer

Terminated

A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety

Obesity

United States, Canada
University of California, San Francisco
California Breast Cancer Research Program

Completed

Telephone-Based Decision Support for Rural Patients

Breast Cancer

United States
Institute for Clinical and Experimental Medicine

Recruiting

Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP (UNLOAD-AMI)

Myocardial Infarction | Shock, Cardiogenic | Remodeling, Ventricular

Czechia
Pfizer

Completed

ACTiF- Assessment of Closed Tibial Fractures

Tibial Fractures

United States, Australia, Canada, Spain, Turkey, Croatia, India, Bosnia and Herzegovina, Japan, Russian Federation, South Africa
Pfizer

Completed

A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The Skin

Smoking Cessation

United States
Duke University
National Institute on Drug Abuse (NIDA); Pfizer

Completed

Adaptive Pharmacotherapy for Smoking Cessation

Nicotine Dependence

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Advanced Solid Tumors

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Solid Tumors

United States
Pfizer

Completed

Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

Sarcoma, Ewing's

United States, United Kingdom
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Study of CP-461 in Patients With Advanced Renal Cell Cancer

Renal Cell Carcinoma

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

Study Using CP-461 to Treat Advanced Prostate Cancer

Prostate Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Pfizer

Terminated

Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

Obesity

United States
Pfizer

Completed

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Dyslipidemia

United States
Albert Einstein College of Medicine
National Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...

Active, not recruiting

A Trial of Directly Observed and Long-term Varenicline

Tobacco Use Disorder | Opioid-use Disorder

United States

Search clinical trials for: varenicline (CP-526,555)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations